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ysis, was defined as the first infection identified following
a gap of at least 30 days in antibiotic use. The treatment
episode ended when there were no additional antibiotics
prescribed or infection-related outpatient medical visits
for 21 consecutive days. The costs of antibiotics, visits,
and tests were documented over the course of the epi-
sode. RESULTS: A total of 30,562 patients (11,798 with
sinusitis, 5,636 with otitis media, 7,310 with pharyngitis,
and 5,818 with bronchitis) met the study inclusion crite-
ria. For sinusitis, OM, and pharyngitis, penicillins were
the most widely prescribed antibiotics, followed by mac-
rolides, sulfonamides, cephalosporins, penicillin/B-lacta-
mase inhibitors, tetracyclines and fluroquinilones. Mac-
rolides were the most commonly used antibiotic for
bronchitis (48% of patients). For patients requiring a
switch to a different antibiotic, macrolides were the most
frequent choice. The overall costs per episode were $97
for pharyngitis, $114 for both OM and sinusitis, and
$133 for bronchitis. The proportion of total costs related
to follow-up treatment ranged from 19% for pharyngitis
to 32% for OM. Antibiotics accounted for 19% (for
pharyngitis) to 29% (for sinusitis) of overall costs. CON-
CLUSIONS: The costs of treatment episodes for RTIs are
fairly substantial and vary by condition. While the initial
encounter accounts for the majority of the costs, the ex-
penses associated with the need for additional treatment
are important to consider.
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OBJECTIVE: In addition to information about efficacy
and safety, decision-makers are interested in information
about the impact of new drug treatments on health care
costs. The objective is to determine the impact of using
gatifloxacin versus levofloxacin on total costs among
outpatient adults with community-acquired pneumonia
(CAP). METHODS: Patients were randomized to receive
either gatifloxacin (GAT) or levofloxacin (LEV) once
daily. Data were collected on efficacy, safety, and medi-
cal care resource use from 163 GAT and 176 LEV clini-
cally evaluable patients. Medical care resource use infor-
mation included the dose and duration of the study and
concomitant medications, duration of intensive care unit
(ICU) and non-ICU hospital stay, and number of outpa-
tient physician visits. We used a multivariate regression
analysis to determine the impact of treatment on total
costs. The dependent variable was the logarithm of total
costs to adjust for the left skewness found in the cost
data. The regression analysis controlled for disease sever-
ity, admission to the hospital on the day of (or before)
randomization, and prognostic factors (including age,
presence of comorbidities, and a previous CAP episode
within the last 12 months). RESULTS: GAT achieved a
cure rate of 96% compared to 94% for LEV. Based on
results from the multivariate regression analysis, patients
in the GAT arm could expect total costs that were ap-
proximately 8% lower (on average) than the total costs
incurred by patients in the LEV arm. Patients admitted to
the hospital on the day of (or before) randomization
could expect total costs that were nearly 51 times higher.
Hospital admission on the day of (or before) randomiza-
tion was the only statistically significant driver of ex-
pected total cost. CONCLUSION: GAT shows a trend to
be less costly and have a higher cure rate than LEV for
outpatients with CAP.
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BACKGROUND: In the field of respiratory tract infec-
tions (RTI), concern about the efficiency of various treat-
ments has increased with the introduction of newer anti-
biotics often associated with higher acquisition costs.
These include second-generation macrolides and fluoro-
quinolones, which constitute alternative strategies to
amoxicillin and erythromycin. OBJECTIVES: To evalu-
ate, from a cost-efficacy standpoint, how these newer
agents compare with each other in the treatment of com-
munity acquired RTI in adults. METHODS: Cost-effi-
cacy analyses were done using decision-analysis tech-
niques based on efficacy and safety data of published
clinical trials. The analyses were performed from the per-
spective of a provincial third-party payer. Costs consid-
ered were those of antibiotics, physicians and pharma-
cists services and diagnostic procedures. RTI for which
analyses were performed are: bronchitis, community ac-
quired pneumonia, otitis media, pharyngitis and sinusitis.
Specific antibiotics compared were: azithromycin, cipro-
floxacin, clarithromycin, grepafloxacin, levofloxacin and
ofloxacin. RESULTS: Following a review of the literature
using Medline and Current Contents, 98 articles pub-
lished between January 1986 and December 1999 met
the inclusion criteria and provided efficacy and safety
data for the analyses. Efficacy rates for each antibiotic
did not differ strikingly and various dosages did not nec-
essarily have an impact on efficacy rates. Cost-efficacy
analyses indicate that, among the antibiotics studied, the
lowest cost-efficacy ratios were associated with either
azithromycin or clarithromycin at a dose of 250mg twice
daily. Azithromycin represented the preferred strategy for
the ambulatory treatment of community-acquired pneu-
monia and otitis media, while clarithromycin at a dose of
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250 mg twice daily would be preferable for bronchitis,
pharyngitis and sinusitis. The studied fluoroquinolones
and clarithromycin at a dose of 500 mg twice daily were
dominated strategies for each of the studied RTI. CON-
CLUSION: From a cost-efficacy standpoint clarithromy-
cin and azithromycin would be preferable to fluoro-
quinolones when an alternate strategy to amoxicillin or
erythromycin is needed.
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OBJECTIVES: The prophylaxis of infection in hysterec-
tomy is necessary because it decreases the amount of
postoperative complications. It has been shown that ce-
furoxime is an effective antibiotic for prevention of infec-
tious complications after abdominal hysterectomy. It has
a bactericidal activity against most pathogens which can
lead to wound failure and prolonged the duration of hos-
pitalization. But pharmacoeconomic evaluation is not per-
formed in the numerous investigations. METHODS: 40
women were randomized in equal groups to receive ce-
furoxime 1,5 g i.v. before start of hysterectomy (group I)
and combination of ampicillin 4,0 g/day i.m. and genta-
mycin 5 mg/kg/day i.m. during 5 days after hysterectomy
(group II). The last method is commonly used in city gy-
necological departments. General condition, temperature,
pulse, condition of postoperative wounds, vaginal dis-
charges were evaluated every day by means of a score
scale. The sum of scores was performed as total clinical
score (TCS). Cost-minimization analysis was performed
for evaluation of economic outcomes of the treatment.
RESULTS: Clinical efficacy of the studied regimens was
equal because the dynamic of TCS coincided in both
groups (100% and 95% accordingly). Condition of
wounds was excellent and pathogenic microorganisms
were not performed. But in group II were detected skin
rash (3 cases) and infectious infiltrate in the place of in-
jection (1 case). Duration of hospitalization was similar
in both groups. But total cost in group I was less by
17.7% than in group II (p  0.05) because acquisition
cost was more in group II. CONCLUSIONS: Prophylaxis
of infectious complications in hysterectomy by cefuroxime
is as effective as combination postoperative treatment
with ampicillin plus gentamycin. Cefuroxime has an eco-
nomic advantage and less danger for patients. This sim-
ple method of prophylaxis indicates more compliance
and less cost and may be recommended for most cases of
hysterectomy.
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OBJECTIVES: Adults presenting with acute sore throats
is one of the most common complaints encountered by
primary care clinicians, yet the proper management of
adult patients with pharyngitis is still somewhat contro-
versial. This study proposes to identify the appropriate
clinical management of adult pharyngitis using both cost-
benefit analysis and cost-effectiveness analysis METH-
ODS: Cost-Benefit Analysis and Cost-Effectiveness Anal-
ysis. Six management strategies were considered in these
analyses: empiric treatment, performing a rapid test, ob-
taining a bacterial culture, empiric treatment with a con-
firmatory bacterial culture, or a combination of the rapid
test with a bacterial culture of negative rapid tests. In ad-
dition, the study incorporates differing probabilities of
streptococcal disease based upon on previously published
symptomatically derived logistic regression scores. Using
an internet-based survey, information is collected on un-
dergraduate and graduate students’ willingness-to-pay
and time trade-off of presented health states. RESULTS:
Preliminary results indicate that patients presenting with
3 or more indicative symptoms (3 days of fever 39C,
tender anterior cervical nodes, enlarged tonsils with pu-
rulent exudates, and lack of cough) should be treated em-
pirically. Those adult patients that complain of only two
symptoms should be managed by a combination of a
rapid diagnostic test with a bacterial culture on those
rapid tests with negative results. CONCLUSIONS: This
study presents findings that should provide clinicians
with a better guide in the treatment of adult patients with
pharyngitis. Performing normative analyses of currently
accepted clinical management, the study employs adult’s
preferences as well as variation in severity of symptoms.
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OBJECTIVE: The objective of this study was to develop
a pharmacoeconomic model which compared the differ-
ence in cost-effectiveness (CE) between a Multiple-daily-
dosing (MDD) protocol of aminoglycosides (AG) man-
aged by a Clinical Pharmacokinetic Dosing Service (CPS)
and a protocol for Once-daily-dosing (ODD), from the
perspective of a Managed Care Organization. METHOD:
Event rates for both clinical effectiveness and aminogly-
